13 terminated. 13 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Terminated 13 |
| Phase 1 | 2 | Terminated 2 |
Follow Alopecia: new trials by email Literature Review of Alopecia trials Research Report on Alopecia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata Amlitelimab, Placebo - Alopecia Areata | Phase 2 | Terminated | Sanofi | 166 | 2024-06-06 | 2026-08-10 |
| A Study of KL130008 in Adults With Severe Alopecia Areata KL130008/Placebo - Alopecia Areata | Phase 2 | Terminated | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 114 | 2022-11-09 | 2026-05-12 |
| A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata Deucravacitinib, Placebo - Alopecia Areata | Phase 2 | Terminated | Bristol-Myers Squibb | 94 | 2022-11-08 | 2025-05-31 |
| PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA PF-06651600, Placebo - Alopecia Areata | Phase 2 | Terminated | Pfizer | 71 | 2020-09-15 | 2025-07-11 |
| ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT) ATI 502 0.46% Topical Solution - Alopecia Areata, Alopecia Universalis | Phase 2 | Terminated | Aclaris Therapeutics, Inc. | 56 | 2019-01-15 | 2020-10-06 |
| A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata ATI-50002 high dose, ATI-50002 low dose, Placebo - Alopecia Areata | Phase 2 | Terminated | Aclaris Therapeutics, Inc. | 129 | 2017-11-29 | 2020-06-05 |
| Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata. LEO 124249, Ointment vehicle - Alopecia Areata | Phase 2 | Terminated | LEO Pharma | 13 | 2017-10-30 | 2025-02-24 |
| MLE4901 vs. Placebo for the Treatment of PCOS MLE4901, Placebo - Polycystic Ovary Syndrome (PCOS) | Phase 2 | Terminated | Millendo Therapeutics US, Inc. | 55 | 2016-07-01 | 2021-02-01 |
| A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA) Placebo Cream, Ruxolitinib Phosphate Cream - Alopecia Areata | Phase 2 | Terminated | Incyte Corporation | 90 | 2015-11-18 | 2020-12-16 |
| A Study of Secukinumab for the Treatment of Alopecia Areata Secukinumab, Placebo - Alopecia Areata | Phase 2 | Terminated | Icahn School of Medicine at Mount Sinai | 11 | 2015-11-01 | 2021-03-11 |
| Evaluation of the Efficacy and Tolerability of Treatment With Interleukin-2 in Severe and Resistant Alopecia Areata Interleukin-2 - Alopecia Areata | Phase 1 / Phase 2 | Terminated | Centre Hospitalier Universitaire de Nice | 4 | 2012-11-01 | 2022-08-31 |
| Safety and Preliminary Efficacy Study of MTS-01 for the Prevention of Alopecia Induced by WHole Brain Radiotherapy MTS-01, Placebo - Alopecia | Phase 2 | Terminated | Mitos Pharmaceuticals | 16 | 2007-04-01 | 2008-07-11 |
| Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions UVA1 Irradiation, UVB Irradiation - Atopic Dermatitis, Psoriasis | Phase 1 / Phase 2 | Terminated | University of Michigan | 28 | 2000-08-01 | 2015-05-22 |
Alopecia Areata (10) · Alopecia universalis (3) · Acne Vulgaris (1) · Dermatitis, Atopic (1) · Hair Diseases (1) · Hirsutism (1) · Hypotrichosis (1) · Lymphoma, T-Cell, Cutaneous (1) · Menstruation Disturbances (1) · Mycosis Fungoides (1) · Polycystic Ovary Syndrome (1) · Psoriasis (1) · Skin Diseases (1) · Striae Distensae (1)
Skin and Connective Tissue Diseases (13) · Hair Diseases (12) · Hypotrichosis (12) · Skin Diseases (12) · Pathological Conditions, Anatomical (5) · Pathological Conditions, Signs and Symptoms (5) · Neoplasms (2) · Signs and Symptoms (2) · Acneiform Eruptions (1) · Adnexal Diseases (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Cysts (1) · Dermatitis (1) · Endocrine System Diseases (1)
Interleukin-2 (1) · Ointments (1) · PF-06651600 (1) · Solutions (1) · deucravacitinib (1) · ruxolitinib (1) · secukinumab (1)
Aclaris Therapeutics, Inc. (2) · Bristol-Myers Squibb (1) · Centre Hospitalier Universitaire de Nice (1) · Icahn School of Medicine at Mount Sinai (1) · Incyte Corporation (1) · LEO Pharma (1) · Millendo Therapeutics US, Inc. (1) · Mitos Pharmaceuticals (1) · Pfizer (1) · Sanofi (1) · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (1) · University of Michigan (1)
United States (9) · Australia (3) · Canada (3) · France (3) · China (2) · Japan (2) · Poland (2) · Argentina (1) · Bulgaria (1) · Chile (1) · Czechia (1) · Denmark (1) · Germany (1) · Italy (1) · Netherlands (1)
John J Voorhees, MD (1) · Kathleen Butler, MD (1) · Mark Lebwohl, MD (1) · Xingqi Zhang (1)
PMID 18645136, PMID 24872229, PMID 28619556, PMID 38263353, PMID 41917311, PMID 42481842
2016 (1), 2017 (1)